NetraMark Holdings (XCNQ:AIAI) Interest Expense : C$0.00 Mil (TTM As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is NetraMark Holdings Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. NetraMark Holdings's interest expense for the three months ended in Mar. 2024 was C$ 0.00 Mil. Its interest expense for the trailing twelve months (TTM) ended in Mar. 2024 was C$0.00 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. NetraMark Holdings's Operating Income for the three months ended in Mar. 2024 was C$ -0.72 Mil. NetraMark Holdings's Interest Expense for the three months ended in Mar. 2024 was C$ 0.00 Mil. NetraMark Holdings has no long-term debt ⁽¹⁾. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

(1) Note: An indication of "no long-term debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

NetraMark Holdings Interest Expense Historical Data

The historical data trend for NetraMark Holdings's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NetraMark Holdings Interest Expense Chart

NetraMark Holdings Annual Data

Trend

Sep20

Sep21

Sep22

Sep23

Interest Expense

NetraMark Holdings Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Sep23	Dec23	Mar24
Interest Expense	Get a 7-Day Free Trial										-	-	-	-	-

NetraMark Holdings Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was C$0.00 Mil.

NetraMark Holdings (XCNQ:AIAI) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

NetraMark Holdings's Interest Expense for the three months ended in Mar. 2024 was C$0.00 Mil. Its Operating Income for the three months ended in Mar. 2024 was C$-0.72 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Mar. 2024 was C$0.00 Mil.

NetraMark Holdings's Interest Coverage for the quarter that ended in Mar. 2024 is calculated as

NetraMark Holdings had no long-term debt ⁽¹⁾.

The higher the ratio, the stronger the company's financial strength is.

Good Sign:

NetraMark Holdings Inc has no debt.

NetraMark Holdings (XCNQ:AIAI) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » NetraMark Holdings Inc (XCNQ:AIAI) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

AINMF:USA

Address

1655 Dupont Street, Suite 101, Toronto, ON, CAN, M6P 3T1

Website

https://www.nurosene.com

NetraMark Holdings Inc is focused on the application of a totally unique Artificial Intelligence (AI) / Machine Learning (ML) solution targeted at the pharmaceutical industry in order to de-risk clinical trials. NetraMark has a proprietary technology that is capable of cutting through the combinatorial complexity that comes with dealing with heterogeneous patient populations to extract precisely defined personas of patients with respect to placebo and drug response, in addition to tolerability and adverse events. By using the client's own contemporaneous data, and having the capacity to learn from small data, the NetraAI tech extracts these personas to equip pharmaceutical companies with strategies to optimize their next trials for success.

Executives

Andrew Parks

Director

NetraMark Holdings (XCNQ:AIAI) Headlines

No Headlines